Literature DB >> 22012397

A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours.

Benjamin Beck1, Gregory Driessens, Steven Goossens, Khalil Kass Youssef, Anna Kuchnio, Amélie Caauwe, Panagiota A Sotiropoulou, Sonja Loges, Gaelle Lapouge, Aurélie Candi, Guilhem Mascre, Benjamin Drogat, Sophie Dekoninck, Jody J Haigh, Peter Carmeliet, Cédric Blanpain.   

Abstract

Angiogenesis is critical during tumour initiation and malignant progression. Different strategies aimed at blocking vascular endothelial growth factor (VEGF) and its receptors have been developed to inhibit angiogenesis in cancer patients. It has become increasingly clear that in addition to its effect on angiogenesis, other mechanisms including a direct effect of VEGF on tumour cells may account for the efficiency of VEGF-blockade therapies. Cancer stem cells (CSCs) have been described in various cancers including squamous tumours of the skin. Here we use a mouse model of skin tumours to investigate the impact of the vascular niche and VEGF signalling on controlling the stemness (the ability to self renew and differentiate) of squamous skin tumours during the early stages of tumour progression. We show that CSCs of skin papillomas are localized in a perivascular niche, in the immediate vicinity of endothelial cells. Furthermore, blocking VEGFR2 caused tumour regression not only by decreasing the microvascular density, but also by reducing CSC pool size and impairing CSC renewal properties. Conditional deletion of Vegfa in tumour epithelial cells caused tumours to regress, whereas VEGF overexpression by tumour epithelial cells accelerated tumour growth. In addition to its well-known effect on angiogenesis, VEGF affected skin tumour growth by promoting cancer stemness and symmetric CSC division, leading to CSC expansion. Moreover, deletion of neuropilin-1 (Nrp1), a VEGF co-receptor expressed in cutaneous CSCs, blocked VEGF's ability to promote cancer stemness and renewal. Our results identify a dual role for tumour-cell-derived VEGF in promoting cancer stemness: by stimulating angiogenesis in a paracrine manner, VEGF creates a perivascular niche for CSCs, and by directly affecting CSCs through Nrp1 in an autocrine loop, VEGF stimulates cancer stemness and renewal. Finally, deletion of Nrp1 in normal epidermis prevents skin tumour initiation. These results may have important implications for the prevention and treatment of skin cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22012397     DOI: 10.1038/nature10525

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  29 in total

Review 1.  Maintaining hematopoietic stem cells in the vascular niche.

Authors:  Mark J Kiel; Sean J Morrison
Journal:  Immunity       Date:  2006-12       Impact factor: 31.745

2.  Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.

Authors:  Qi Pan; Yvan Chanthery; Wei-Ching Liang; Scott Stawicki; Judy Mak; Nisha Rathore; Raymond K Tong; Joe Kowalski; Sharon Fong Yee; Glenn Pacheco; Sarajane Ross; Zhiyong Cheng; Jennifer Le Couter; Greg Plowman; Franklin Peale; Alexander W Koch; Yan Wu; Anil Bagri; Marc Tessier-Lavigne; Ryan J Watts
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

3.  Rapid vessel regression, protease inhibition, and stromal normalization upon short-term vascular endothelial growth factor receptor 2 inhibition in skin carcinoma heterotransplants.

Authors:  Daniel W Miller; Silvia Vosseler; Nicolae Mirancea; Daniel J Hicklin; Peter Bohlen; Hans E Völcker; Frank G Holz; Norbert E Fusenig
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

4.  The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin.

Authors:  V Vasioukhin; L Degenstein; B Wise; E Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

Review 6.  VEGF-targeted therapy: mechanisms of anti-tumour activity.

Authors:  Lee M Ellis; Daniel J Hicklin
Journal:  Nat Rev Cancer       Date:  2008-07-03       Impact factor: 60.716

7.  Loss of vascular endothelial growth factor a activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation.

Authors:  Heidemarie Rossiter; Caterina Barresi; Johannes Pammer; Michael Rendl; Jody Haigh; Erwin F Wagner; Erwin Tschachler
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

Review 8.  Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.

Authors:  L Witte; D J Hicklin; Z Zhu; B Pytowski; H Kotanides; P Rockwell; P Böhlen
Journal:  Cancer Metastasis Rev       Date:  1998-06       Impact factor: 9.264

9.  Asymmetric cell divisions promote Notch-dependent epidermal differentiation.

Authors:  Scott E Williams; Slobodan Beronja; H Amalia Pasolli; Elaine Fuchs
Journal:  Nature       Date:  2011-02-17       Impact factor: 49.962

Review 10.  Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors.

Authors:  Jason M Butler; Hideki Kobayashi; Shahin Rafii
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

View more
  208 in total

1.  Cancer stem cells. VEGF promotes stemness.

Authors:  Sarah Seton-Rogers
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

2.  Tumour biology: Skin-cancer stem cells outwitted.

Authors:  Salvador Aznar Benitah
Journal:  Nature       Date:  2011-10-19       Impact factor: 49.962

3.  Autocrine platelet-derived growth factor-vascular endothelial growth factor receptor-related (Pvr) pathway activity controls intestinal stem cell proliferation in the adult Drosophila midgut.

Authors:  David Bond; Edan Foley
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

4.  VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.

Authors:  Hira Lal Goel; Cheng Chang; Bryan Pursell; Irwin Leav; Stephen Lyle; Hualin Simon Xi; Chung-Cheng Hsieh; Helty Adisetiyo; Pradip Roy-Burman; Ilsa M Coleman; Peter S Nelson; Robert L Vessella; Roger J Davis; Stephen R Plymate; Arthur M Mercurio
Journal:  Cancer Discov       Date:  2012-07-09       Impact factor: 39.397

Review 5.  Centrosomes in spindle organization and chromosome segregation: a mechanistic view.

Authors:  Patrick Meraldi
Journal:  Chromosome Res       Date:  2016-01       Impact factor: 5.239

Review 6.  Cancer Stem Cells: The Architects of the Tumor Ecosystem.

Authors:  Briana C Prager; Qi Xie; Shideng Bao; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2019-01-03       Impact factor: 24.633

Review 7.  CD133-targeted niche-dependent therapy in cancer: a multipronged approach.

Authors:  Anthony B Mak; Caroline Schnegg; Chiou-Yan Lai; Subrata Ghosh; Moon Hee Yang; Jason Moffat; Mei-Yu Hsu
Journal:  Am J Pathol       Date:  2014-02-28       Impact factor: 4.307

8.  NRP-1 interacts with GIPC1 and α6/β4-integrins to increase YAP1/∆Np63α-dependent epidermal cancer stem cell survival.

Authors:  Daniel Grun; Gautam Adhikary; Richard L Eckert
Journal:  Oncogene       Date:  2018-05-14       Impact factor: 9.867

9.  Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic.

Authors:  Ntube N O Ngalame; Erik J Tokar; Rachel J Person; Yuanyuan Xu; Michael P Waalkes
Journal:  Toxicol Sci       Date:  2014-01-15       Impact factor: 4.849

Review 10.  Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion.

Authors:  Martine Perrot-Applanat; Melanie Di Benedetto
Journal:  Cell Adh Migr       Date:  2012-11-01       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.